USA - NYSE:FMS - US3580291066 - ADR
The current stock price of FMS is 27.24 USD. In the past month the price increased by 6.49%. In the past year, price increased by 30.15%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 12.92 | 103.91B | ||
| CI | THE CIGNA GROUP | 10.74 | 80.55B | ||
| LH | LABCORP HOLDINGS INC | 18.46 | 23.23B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.67 | 20.37B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 153.35 | 20.10B | ||
| HIMS | HIMS & HERS HEALTH INC | 60.98 | 11.03B | ||
| DVA | DAVITA INC | 13.33 | 9.24B | ||
| GH | GUARDANT HEALTH INC | N/A | 9.00B | ||
| RDNT | RADNET INC | 231.69 | 6.42B | ||
| CHE | CHEMED CORP | 19.52 | 6.36B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 45.31 | 5.94B | ||
| OPCH | OPTION CARE HEALTH INC | 20.67 | 4.53B |
Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. The company is headquartered in Bad Homburg Vor Der Hohe, Hessen and currently employs 112,445 full-time employees. The firm provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. The company has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. The company develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The company owns, operates, or manages dialysis clinics sells products to other dialysis providers.
FRESENIUS MEDICAL CARE-ADR
Else-Kroener-Strasse 1
Bad Homburg vor der Hohe HESSEN 61352 DE
CEO: Rice Powell
Employees: 112445
Phone: 4961726090
Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. The company is headquartered in Bad Homburg Vor Der Hohe, Hessen and currently employs 112,445 full-time employees. The firm provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. The company has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. The company develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The company owns, operates, or manages dialysis clinics sells products to other dialysis providers.
The current stock price of FMS is 27.24 USD. The price increased by 1.19% in the last trading session.
FRESENIUS MEDICAL CARE-ADR (FMS) has a dividend yield of 3.1%. The yearly dividend amount is currently 0.69.
FMS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
FMS stock is listed on the New York Stock Exchange, Inc. exchange.
The PE ratio for FRESENIUS MEDICAL CARE-ADR (FMS) is 13.49. This is based on the reported non-GAAP earnings per share of 2.02 and the current share price of 27.24 USD.
FRESENIUS MEDICAL CARE-ADR (FMS) will report earnings on 2025-11-04.
ChartMill assigns a technical rating of 9 / 10 to FMS. When comparing the yearly performance of all stocks, FMS is one of the better performing stocks in the market, outperforming 77.76% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to FMS. FMS has only an average score on both its financial health and profitability.
Over the last trailing twelve months FMS reported a non-GAAP Earnings per Share(EPS) of 2.02. The EPS increased by 17.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.36% | ||
| ROA | 2.1% | ||
| ROE | 4.95% | ||
| Debt/Equity | 0.71 |
25 analysts have analysed FMS and the average price target is 29.49 USD. This implies a price increase of 8.26% is expected in the next year compared to the current price of 27.24.
For the next year, analysts expect an EPS growth of 17.76% and a revenue growth 1.28% for FMS